A Study of S-268019 for the Prevention of COVID-19
NCT05212948
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
9902
Enrollment
INDUSTRY
Sponsor class
Conditions
SARS-CoV-2
Interventions
DRUG:
S-268019-b
DRUG:
Placebo
Sponsor
Shionogi